• Efrat Schwarz Kenan, Michael Friger, Daphna Shochat-Bigon, Hagit Schayek, Rinat Bernstein-Molho, and Eitan Friedman.
• Department of Public Health, Ben-Gurion University of the Negev, Beer Sheba, Israel.
• Anticancer Res. 2018 Aug 1; 38 (8): 4557-4563.

Background/AimSeveral algorithms have been developed to assess the risk of predicting BRCA mutation and breast cancer (BC) risk. The aim of this study was to evaluate the accuracy of these prediction algorithms in the Israeli population.Patients And MethodsRisk for developing breast cancer and the probability for carrying BRCA1/2 mutations using BOADICEA, BRCAPRO, IBIS, MYRIAD and PENN2 models were computed for individuals counseled and genotyped at the Oncogenetics unit in 2000 and 2005. The predicted mutation carriers and BC risks were compared with actual carrier rates by genotyping and BC diagnoses derived from the Israeli National Cancer Registry database.ResultsOverall, 65/648 (10%) study participants were BRCA1/2 mutation carriers. Of 373 cancer-free participants at counseling, 25 had breast cancer by 2016. BOADICEA and BRCAPRO performed best for predicting BRCA mutation (AUC=0.741, 0.738, respectively). No model was clinically useful in predicting breast cancer risk.ConclusionBOADICEA and BRCAPRO outperformed the other tested algorithms in BRCA mutation prediction in Israeli women, but none was valuable in breast cancer risk prediction.Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

30 keywords...

hide…